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Baseline Characteristics
High Risk Arm
(n[628)
Non-High Risk Arm
(n[271)
Age (mean  SD) 77  11 years 74  11 years
Coronary Artery Disease 78% 49%
Atrial Fibrillation 71% 56%
Moderate to Severe Renal Disease 30% 9%
Prior CABG Surgery 54% 17%
NYHA Functional Class III/IV 85% 55%
Functional Mitral Regurgitation 70% 32%
LV Ejection Fraction (mean  SD) 47  14% 56  11%
LVIDs (mean  SD) 4.4  1.1 cm 3.7  0.9 cm
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JECTIVES BIOFLOW-II is a randomized controlled study, comparing the clinical
cacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
erolimus Eluting Stent (XiencePrime) at 2 years in the complete study population
well as in the diabetic and small vessel subgroups, which are known to have a
her risk for cardiac complications. Here we present the outcome through the
nical endpoints Target Lesion Failure (TLF) and Stent Thrombosis (ST).
THODS A total of N¼452 subjects (62.7  10.4, 38-80 yrs) were enrolled in the
ention to Treat population in the BIOFLOW-II study, registered at clinicaltrials.gov
CT01356888). All subjects were stratiﬁed for diabetes and then randomly assigned
1) to receive the Orsiro or the Xience Prime stent. The diabetic subgroup accounted
28.3% N¼128 (Orsiro N¼84, Xience Prime N¼44) of all subjects. The small vessel
ort included all subjects with a reference vessel diameter 2.75mm, accounting
57.3% N¼259 (Orsiro N¼168, Xience Prime N¼91) of all subjects. Clinical follow up
its are performed at 1, 6, 12 months and annually up to 5 years after the procedure.
angiographic images were analyzed by an independent Corelab. All clinical events
re adjudicated by 3 independent clinical events committee.
DINGS All three study groups showed comparable populations in both randomi-
ion arms in terms of demographics, current risk factors, clinical history and lesion/
ssel characteristics. The TLF rate at 24 months was 8.4% for the Orsiro vs. 10.0% for
Xience Prime in the full cohort, 9.7% vs. 9.1% in the diabetic subgroup and 9.4%
13.3% for subjects with small vessel lesions. There was no statistical signiﬁcance
tween the two study arms in any of the three analyzed populations. No ST
ﬁnitive, probable or possible) occurred through 24 months in the Orsiro arm. One
ent alone, very late possible ST, occurred in the diabetic subgroup of the Xience
me arm during the same time.
NCLUSIONS In this RCT the clinical event rates of the Orsiro SES with a biode-
dable polymer the clinical event rates were low and comparable to the Xience
me until 24 months in all three analyzed populations.
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RPOSE Compared to non-calciﬁed lesions, the presence of calciﬁcation at the
get lesion leads not only to a higher incidence of major adverse cardiac events
ACE) during percutaneous coronary intervention but is also associated with a high
quency of inadequate stent expansion, stent fracture, restenosis or revasculari-
ion, and a higher treatment cost.
THODS ORBIT II (49 U.S. sites, 443 subjects) is the ﬁrst prospective trial to
clusively study severely calciﬁed lesions, and included high-risk patients usually
cluded from large trials such as those on dialysis or with a low left ventricular
ction fraction (>25%). Investigators utilized the Diamondback 360 Coronary
bital Atherectomy System (OAS) to modify and prepare severely calciﬁed
ions before stent placement. The OAS utilizes a centrifugal sanding action and is
ﬁrst novel technology to receive FDA approval to treat severely calciﬁed lesions.
e ORBIT II trial 2-year follow-up assessed the following MACE components:
cardiac death, 2) myocardial infarction (MI), and 3) target vessel revascularization
R).RESULTS The ORBIT II 2 year MACE rate and its components will be presented for the
ﬁrst time. We anticipate that the rates will be lower compared to the literature. Low
rates of ORBIT II 1-year MACE (16.4%), cardiac death (3.0%), MI (9.7%), and TVR
(5.9%) were previously reported.
CONCLUSION Modiﬁcation of severely calciﬁed plaque with the OAS improves out-
comes in this difﬁcult-to-treat patient population. Thus, using the OAS as a lesion
preparation tool prior to stent implantation offers patients with severely calciﬁed
coronary lesions a new treatment option.
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BACKGROUND EVEREST II REALISM is a prospective, multi-center, continued access
study to collect data on “real world” use of MitraClip in high risk (HR) and non-high
risk (NHR) patients. Baseline demographics, clinical and acute procedural data are
presented.
METHODS HR was deﬁned as STS score 12% or pre-speciﬁed risk factors. As of
December 2013, 628 HR and 271 NHR patients were enrolled.
RESULTS Mean ages of HR and NHR patients were 77 and 74 years respectively.
Mean STS score in HR was 117%. Baseline characteristics in HR and NHR vary
with respect to extent of co-morbidities and NYHA Class status. A majority of patients
were in NHYA Class III/IV and had atrial ﬁbrillation. A higher percentage of HR pa-
tients had CAD and prior CABG surgery. A majority of HR had functional mitral
regurgitation (MR). In HR, 96% of patients received 1 or 2 MitraClip devices with a
mean hospital stay of 3.2 days. MR 2þ was observed in 90% of patients at discharge.
In NHR, 95% of patients received 1 or 2 MitraClip devices with a mean hospital stay of
2.8 days. MR 2þ was observed in 89% of patients at discharge. Mortality at 30 days
was 4.2% in HR and 1.5% in NHR. There were no intra-procedural deaths in either
group.
CONCLUSION Baseline data indicate that patients treated with MitraClip in REALISM
are elderly and have signiﬁcant co-morbidities. The procedural data demonstrate the
feasibility, acute safety and acute effectiveness of MitraClip in a complex “real world”
US population.
